Merck KGaA

News

Merck KGaA links with AI firm to iron out side-effects durin...

Germany’s Merck KGaA has begun a licensing agreement with Canadian pharma R&D company Cyclica using artificial intelligence (AI) to uncover new drug targets and predict any side effects

News

P&G completes acquisition of Merck KGaA’s OTC division

Procter & Gamble (P&G) has completed its acquisition of Merck KGaA’s Consumer Health business, in a move it hopes will help boost its flagging sales prospects.

Views & Analysis

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

Merck KGaA's bold new approach to cancer immunotherapy

Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.

News

First line kidney cancer could get crowded as Merck KGaA/Pfi...

Competition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO conference with detailed results of their combination of the Bavencio immunother

News

Merck KGaA's BTK drug reduces lesions in relapsing MS patien...

Germany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) class drug evobrutinib reduced occurrence of central nervous system lesion

News

Pfizer/Merck KGaA eye fast review for kidney cancer combo

A combination therapy based around Pfizer and Merck KGaA’s Bavencio has outperformed standard of care in a late-stage trial in untreated but advanced kidney cancer.

Merck KGaA links with AI firm to iron out side-effects durin...

P&G completes acquisition of Merck KGaA’s OTC division

Merck KGaA's bold new approach to cancer immunotherapy

First line kidney cancer could get crowded as Merck KGaA/Pfi...

Merck KGaA's BTK drug reduces lesions in relapsing MS patien...

Pfizer/Merck KGaA eye fast review for kidney cancer combo

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Merck KGaA

Editor's Picks